Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,673.09
(
-0.64%
)
US TECH 100
24,005.60
(
-0.53%
)
Dow Jones
46,575.97
(
-0.89%
)
Brent Oil
103.80
(
3.13%
)
Bitcoin
71,873.08
(
-2.80%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 106479

Thursday, 10/20/2011 2:16:52 AM

Thursday, October 20, 2011 2:16:52 AM

Post# of 257253
SNY reports additional Aubagio (f/k/a teriflunomide) data from phase-3 TEMSO study in RRMS and reveals that the NDA has been accepted by the FDA for review:

http://finance.yahoo.com/news/Oral-Therapy-Teriflunomide-prnews-1797152570.html?x=0&.v=4

Assuming a standard review (the PR would presumably have said so if a priority review), the PDUFA date is in June 2012. The PR above says SNY intends to submit a European MAA in 1Q12, which could allow EU approval in 1H13.

Aubagio is one of the various oral threats to Copaxone, so it bears watching for MNTA and TEVA investors.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now